The price of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) shares last traded on Wall Street fell -5.26% to $1.62.
Based on available information, 2 analysts follow NeuroOne Medical Technologies Corporation (NASDAQ:NMTC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $3.25 and a low of $2.00, we find $2.63. Given the previous closing price of $1.71, this indicates a potential upside of 53.8 percent. NMTC stock price is now 5.60% away from the 50-day moving average and 9.47% away from the 200-day moving average. The market capitalization of the company currently stands at $31.64M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 1 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $2.63 as their price target over the next twelve months.
With the price target reduced from $6 to $2, Craig Hallum Downgraded its rating from Buy to Hold for NeuroOne Medical Technologies Corporation (NASDAQ: NMTC).
In other news, McClurg Ronald W., Chief Financial Officer bought 10,000 shares of the company’s stock on Jun 15. The stock was bought for $10,219 at an average price of $1.02. Upon completion of the transaction, the Chief Financial Officer now directly owns 67,000 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 10, Chief Financial Officer McClurg Ronald W. bought 14,000 shares of the business’s stock. A total of $14,781 was incurred on buying the stock at an average price of $1.06. This leaves the insider owning 57,000 shares of the company worth $92340.0. Insiders disposed of 61,979 shares of company stock worth roughly $0.1 million over the past 1 year. A total of 16.81% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NMTC stock. A new stake in NeuroOne Medical Technologies Corporation shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $139,000. CITADEL ADVISORS LLC invested $58,000 in shares of NMTC during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in NeuroOne Medical Technologies Corporation valued at approximately $24,000. MORGAN STANLEY acquired a new stake in NMTC for approximately $4,000. UBS GROUP AG purchased a new stake in NMTC valued at around $2,000 in the second quarter. In total, there are 15 active investors with 21.60% ownership of the company’s stock.
A candlestick chart of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) showed a price of $1.7600 on Thursday morning. During the past 12 months, NeuroOne Medical Technologies Corporation has had a low of $0.51 and a high of $2.95. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.70, and a quick ratio of 6.00. The fifty day moving average price for NMTC is $1.5340 and a two-hundred day moving average price translates $1.4799 for the stock.
The latest earnings results from NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.09, beating analysts’ expectations of -$0.11 by 0.02. This compares to -$0.18 EPS in the same period last year. The company reported revenue of $1.57 million for the quarter, compared to $40000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3825.0 percent. For the current quarter, analysts expect NMTC to generate $1.9M in revenue.
NeuroOne Medical Technologies Corporation(NMTC) Company Profile
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
